Literature DB >> 2645366

Heterogeneous bullous pemphigoid antibodies: detection and characterization by immunoblotting when absent by indirect immunofluorescence.

P Bernard1, L Didierjean, F Denis, J H Saurat, J M Bonnetblanc.   

Abstract

We studied sera from 59 patients with bullous pemphigoid (BP) and 25 control subjects (normal volunteers, patients with pemphigus, psoriasis, eczema, or other dermatoses) by western blotting analysis on protein bands from normal human heat-separated epidermis. BP sera reacted with four protein bands that were not detected by control sera: two major bands at 220-240 and 165 kD and two faint bands at 190 and 95 kD. Three of these bands were significantly associated with BP: 220-240 kd (51% of the BP patients; p less than 0.001), 165 kD (49%; p less than 0.001) and 190 kD (20%; p less than 0.05). These results are consistent with a molecular heterogeneity of BP antibodies, because each individual BP serum showed a distinctive pattern of reactivity. Thirty out of the 59 BP sera contained anti-basement membrane zone antibodies demonstrable by indirect immunofluorescence (IIF). All these IIF positive BP sera reacted by immunoblotting with at least one protein band: 23 (77%) with the 220-240-kD band and 21 (70%) with the 165-kD band. Furthermore, 45% of the 29 IIF negative BP sera showed a reactivity with the 220-240-kD band and/or the 165-kD band. These results indicate that western immunoblotting might be a more sensitive method for the detection of circulating BP antibodies than IIF techniques, including IIF on salt split skin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645366     DOI: 10.1111/1523-1747.ep12276689

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180.

Authors:  G J Giudice; H L Squiquera; P M Elias; L A Diaz
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

3.  Immunoblot assay to study the pemphigus vulgaris antigen in normal human epidermis and COLO-16 cell line.

Authors:  A Mohimen; A R Ahmed
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  An extract from cultured human keratinocytes that contains the major autoantigens related to autoimmune bullous skin diseases.

Authors:  F Batteux; N Franck; P Jaffray; M Raulo; C Prost; M Leibowitch; J P Escande; B Weill
Journal:  J Clin Immunol       Date:  1997-05       Impact factor: 8.317

5.  Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome.

Authors:  L A Diaz; H Ratrie; W S Saunders; S Futamura; H L Squiquera; G J Anhalt; G J Giudice
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Comparison of an indirect immunofluorescence assay and a modified sensitive immunoblot assay for the study of the autoantibody in pemphigus vulgaris.

Authors:  A Mohimen; A R Ahmed
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 7.  Recent advances on the 180-kDa epidermal antigen in autoimmune subepidermal bullous skin diseases.

Authors:  P Bernard
Journal:  Springer Semin Immunopathol       Date:  1992

Review 8.  Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.

Authors:  Angelo Ruggiero; Matteo Megna; Alessia Villani; Rosita Comune; Gabriella Fabbrocini; Francesca di Vico
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-14

9.  Immunochemical characterization of three components of the hemidesmosome and their expression in cultured epithelial cells.

Authors:  D H Klatte; M A Kurpakus; K A Grelling; J C Jones
Journal:  J Cell Biol       Date:  1989-12       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.